Use of a Silicone Sensor to Protect Fragile Neonatal Skin in Moderately Preterm Infants Needing Continuous Monitoring: the PRO-NEO-SKIN (Protect Neonatal Skin) Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- skin integrity
研究概览
简要总结
Neonates, especially when born prematurely, have an inherently fragile skin, due to the overall prematurity and to the immature composition of epidermidis and skin dermal structures. In these patients, skin lesions are a frequent entry site for pathogens that may disseminate into the bloodstream causing systemic infection and sepsis.
Preterm neonates admitted in a Nursery feature medical conditions that require continuous monitoring of vital signs and parameters, namely heart rate, oxygen saturation, and systemic blood pressure. As a result, skin sensors used for monitoring are needed to remain in place on a 24/7 basis for very long periods - up to 3-4 months in the most extremely premature ones. Use of non-silicone adhesive sensors is associated to skin/dermal injuries, damage, loss of substance, bleeding and/or peeling in a way that is linearly related with the time of maintainance of the sensor.
As above mentioned, skin damage associated with disruptions of the skin barrier are a risk factor for a number of negative, clinically measurable outcomes of prematurity (such as skin infection, epidermal transpiration and subsequent systemic dehydration, scars, etc.) . In addition, skin colonization and subsequent systemic translocation by pathogens occurs more frequently under skin damage conditions. Hence, bloodstream infections originating from the skin reservoir, as well as central line- associated bloodstream infections (CLABSI), are features that are known to be negative outcomes of all conditions leading to skin damage and epidermal skin barrier impairment.
Recently, a first-in-class pulse oximetry sensor using a silicone adhesive to protect fragile skin and improve repositionability has become commercially available (Nellcor™ OxySoft™ SpO2 sensor). This innovation might obviously confer health benefits to an inherently fragile population like preterm infants. However, no study so far explored this area in this specific population of fragile patients.
The aim of this proposal is therefore to study whether preterm neonates may have clinically-measurable benefits from using this innovative device, compared with infants who use the comparator device that is currently used per standard of care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 0 Days 至 1 Day(Child)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Preterm Infants 32+0 - 37+0 wGA (male and female)
- •Need for hospitalization after birth (any cause)
- •Absence of conditions related to congenital anomalies involving - or expected to involve- the skin
- •Haematocrit at enrolment with values in the range 40-60 mg/dl
- •Absence of immediate life-threatening conditions
- •Written IC obtained from parents/legal guardian
排除标准
- •Parental refusal
- •Death prior to the first investigational assessment
研究组 & 干预措施
Arm A
use of the investigational sensor
干预措施: Nellcor™ OxySoft™ (Device)
Arm B
use of a SOC , comparator sensor
干预措施: MasimoRD SET NeoPt-500 (Device)
结局指标
主要结局
skin integrity
时间窗: 14 days
measurement of Transepidermal water loss (TEWL), this last being a key indicator of the skin barrier function,
次要结局
- 6. length of hospital stay (LOS)(14 days)
- 1. Late-onset sepsis(14 days)
- 2. CLABSI(14 days)
- 3. skin infection(14 days)
- 4. adverse effects/intolerances to treatment(14 days)
- 5. weight difference from admission to discharge(14 days)
研究者
Paolo Manzoni Study Group
Prof.
Paolo Manzoni
